Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1

BACKGROUND: Galectin-3 (Gal-3) is a β-galactoside-binding lectin that is highly expressed within the tumor microenvironment of aggressive cancers and has been suggested to predict a poor response to immune checkpoint therapy with the anti-PD-1 monoclonal antibody pembrolizumab. We aimed to assess if...

Descripción completa

Detalles Bibliográficos
Autores principales: Mabbitt, Joseph, Holyer, Ian D., Roper, James A., Nilsson, Ulf J., Zetterberg, Fredrik R., Vuong, Lynda, Mackinnon, Alison C., Pedersen, Anders, Slack, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493609/
https://www.ncbi.nlm.nih.gov/pubmed/37701441
http://dx.doi.org/10.3389/fimmu.2023.1250559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493609/
https://www.ncbi.nlm.nih.gov/pubmed/37701441
http://dx.doi.org/10.3389/fimmu.2023.1250559

Ejemplares similares